Experimental study of the allergenic potential of a drug based on hyaluronidase PEGylated using the technology of electron beam synthesis

n t r o d u c t i o n . Hyaluronidase is an enzyme preparation widely used in medicine, including ophthalmology. Hyaluronidase, having a protein structure, carries a potential danger in the form of undesirable allergic reactions. To avoid allergenic effects, protein structures are modified by combining with a polymer carrier, for example, by polyethylene glycol (PEG).

A i m . To study the possible allergenic potential of hyaluronidase, PEGylated using the technology of electron beam synthesis, with various routes of administration.

M a t e r i a l s a n d m e t h o d s . The object of the study is PEGylated hyaluronidase (PEG-Hyal). Experimental animals are hybrid mice and guinea pigs. Seven types of experiments were carried out: anaphylactogenic activity; conjunctival challenge test; cutaneous applications; delayed-type hypersensitivity (DTH); active cutaneous anaphylaxis; indirect mast cell degranulation; inflammatory response to concanavalin A (ConA).

R e s u l t s . When studying anaphylactogenic activity, an anaphylactic reaction was not observed in guinea pigs. The conjunctival challenge test also revealed no signs of hypersensitivity to the drug. In the study of sensitization, no development of local allergic reactions was observed. In experiments to the study DTH in mice, there were no significant differences for the DTH index in the experimental and control groups. The assessment of active skin anaphylaxis has been showed that the diameter of the stained spot did not significantly differ in both experimental groups from the control one. In indirect mast cell degranulation experiments, it was found that there was no statistically significant change in the mast cell degranulation index. Evaluation of the allergenic potential of PEG-Hyal in the inflammatory response to ConA showed that there is no statistically significant difference between the experimental and control groups.

C o n c l u s i o n . Based on the results of the experiments, it can be concluded that PEG-Hyal does not have an allergenic potential in various routes of administration, which significantly expands the possibilities of its clinical use.

1. Dunn A.L., Heavner J.E., Racz G., Day M. Hyaluronidase: a review of approved formulations, indications and off-label use in chronic pain management. Expert. Opin. Biol. Ther. 2010;10(1):127-131. DOI: 10.1517/14712590903490382.

2. Jung H. Hyaluronidase: An overview of its properties, applications, and side effects. Arch. Plast. Surg. 2020;47(4):297-300. DOI: 10.5999/aps.2020.00752.

3. Kim M.S., Youn S., Na C.H., Shin B.S. Allergic reaction to hyaluronidase use after hyaluronic acid filler injection. J. Cosmet. Laser Ther. 2015;17(5):283-5. DOI: 10.3109/14764172.2015.1007069.

4. Sharma S.C., Lahiri A. Use of hyaluronidase in plastic surgery: а review. J. Plast. Reconstr. Aesthet. Surg. 2021;74(7):1610-1614. DOI: 10.1016/j.bjps.2021.03.125.

5. Mayor R., Gautam P., Agarwal M. et al. Hyaluronidase sensitivity: Our experience. Indian J. Ophthalmol. 2016;64(10):789-790. DOI: 10.4103/0301-4738.195008.

6. Ahluwalia H.S., Lukaris A., Lane C.M. Delayed allergic reaction to hyaluronidase: a rare sequel to cataract surgery. Eye (Lond.). 2003;17(2):263-266. DOI: 10.1038/sj.eye.6700243.

7. Raichura N.D., Alam M.S., Jaichandran V.V. et al. Hyaluronidase allergy mimicking orbital cellulitis. Orbit. 2018;37(2):149-153. DOI: 10.1080/01676830.2017.1383465.

8. Murray G., Convery C., Walker L., Davies E. Guideline for the safe use of hyaluronidase in aesthetic medicine, including modified high-dose protocol. J. Clin. Aesthet. Dermatol. 2021;14(8):Е69-Е75.

9. Wu L., Liu X., Jian X. et al. Delayed allergic hypersensitivity to hyaluronidase during the treatment of granulomatous hyaluronic acid reactions. J. Cosmet. Dermatol. 2018;17(6):991-995. DOI: 10.1111/jocd.12461.

10. Scolaro R.J., Crilly H.M., Maycock E.J. et al. Australian and New Zealand Anaesthetic Allergy Group perioperative anaphylaxis investigation guidelines. Anaesth. Intensive Care. 2017;45(5):543-555. DOI: 10.1177/0310057X1704500504.

11. Madonov P. G., Ershov K. I., Dubrovin А. V. et al. Electron- beam modification of preparations of the albuminous nature for improvement of their pharmacological properties. Medicine and Education in Siberia. 2013;4:83. (In Russ.)

12. Dygay A.M., Pershina O.V., Krupin V.A. et al. Study of antifibrotic activity of modified and native hyaluronidase at pulmonary fibrosis. Siberian Scientific Medical Journal. 2017;37(4):5-10. (In Russ.)

13. Skurihin E.G., Pershina O.V., Krupin V.A. et al. Eff ects and mechanisms of pegylated hyaluronidaze in c57BL/6 mice under bleomycin induced pulmonary fibrosis. Pathogenesis. 2015;13(3):56-64. (In Russ.)

14. Dygai A.M., Zyuz’kov G.N., Gurto R.V. et al. Effect of pegylated hyaluronate-endo-β-N-acetylhexo saminidase on humoral mechanisms regulating the functions of progenitor cells during chronic hepatitis. Bulletin Experimental Biology and Medicine. 2013;155(2):140-143. (In Russ.)

15. Dygai A.M., Zyuz’kov G.N., Zhdanov V.V. et al. Method of stimulating liver stem cell differentiation in vitro in tissue-specific direction: Patent RUS 2477752. 17.02.2012. (In Russ.)

16. Dygai A.M., Zyuz’kov G.N., Zhdanov V.V. et al. Effect of hyaluronidase immobilized using electron-beam synthesis nanotechnology on sensitivity of progenitor cells to regulatory factors. Bulletin of Experimental Biology and Medicine. 2011;151(1):150-153. DOI: 10.1007/s10517-011-1277-0.

17. Lyubimov B.I., Kovalenko L.P., Fedoseeva V.N. (2000). Guidelines for the Evaluation of Allergenic Properties of Pharmacological Substances. Moscow. P. 25–32. (In Russ.)

18. Weigle W.O., Cochrane C.G., Dixon F.J. Anaphylactogenic properties of soluble antigen–antibody complexes in the guinea pig and rabbit. J. Immunol. 1960;85:469-477.